Lung Function

Healio Pulmonology has compiled the top news on COPD posted in 2023.

Adults with moderate to severe persistent asthma receiving rademikibart every 2 weeks showed greater improvements in lung function at week 12 compared with patients assigned placebo, according to topline results from a phase 2b trial.

Over time, adults with severe obstructive sleep apnea had more high attenuation areas on CT and lower lung function, which may signal early interstitial lung disease, according to data published in Annals of the American Thoracic Society.

Adults with moderate to severe COPD and type 2 inflammation receiving dupilumab vs. placebo had fewer exacerbations and improved lung function at 52 weeks, according to topline results from the phase 3 NOTUS trial.

Individuals aged 15 to 50 years faced heightened odds for COPD if they had been exposed to household air pollution and elevated ambient ozone levels, according to results published in Thorax.

Patients with severe alpha-1 antitrypsin deficiency had improved survival with intravenous plasma-purified alpha-1 antitrypsin therapy, according to results published in American Journal of Respiratory and Critical Care Medicine.

Receipt of 4D-710, an aerosolized gene therapy, resulted in high cystic fibrosis transmembrane conductance regulator protein expression levels in patients with cystic fibrosis, according to a company press release.

For patients with cystic fibrosis, exercise helps with disease management, and exercise tests allow clinicians to assess lung health, muscle strength and treatment response, according to a press release from University of Portsmouth.

Residents in urban areas experienced reductions in lung function when exposed to increased levels of propylene oxide, according to study results published in CHEST.

The FDA granted breakthrough therapy designation to an oral lysophosphatidic acid receptor 1 antagonist that lowered the rate of percent-predicted FVC decline among patients with progressive pulmonary fibrosis.